| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dorothee Herlyn | Q119728705 |
| P2093 | author name string | Tianqian Zhang | |
| P2860 | cites work | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer | Q24684241 | ||
| Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model | Q24805875 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse | Q28204295 | ||
| Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms | Q73803447 | ||
| Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer | Q73877537 | ||
| In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma | Q74121696 | ||
| Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer | Q79367332 | ||
| Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited | Q79464087 | ||
| Necrotic tumor cell death in vivo impairs tumor-specific immune responses | Q79609715 | ||
| Cancer immunotherapy | Q80066933 | ||
| Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy | Q80209418 | ||
| Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients | Q80216646 | ||
| Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma | Q80243204 | ||
| Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma | Q81208645 | ||
| Immunotherapy and chemotherapy--a practical partnership | Q81703535 | ||
| Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts | Q82359485 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma | Q32034092 | ||
| Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer | Q33257718 | ||
| A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma | Q33342339 | ||
| Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). | Q33343994 | ||
| Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial | Q33361488 | ||
| Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer | Q33374300 | ||
| Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model | Q34098565 | ||
| Photodynamic therapy and anti-tumour immunity. | Q34105703 | ||
| Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies | Q34276476 | ||
| Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? | Q34452706 | ||
| Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. | Q34507119 | ||
| Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts | Q34523090 | ||
| Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer | Q34574205 | ||
| Immunochemotherapy in indolent non-Hodgkin's lymphoma | Q34662952 | ||
| Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma | Q34662961 | ||
| The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma | Q35047632 | ||
| Immunotherapy: new options in breast cancer treatment | Q35160235 | ||
| Immunotherapy as part of combinations for the treatment of cancer | Q35177544 | ||
| Immunomodulation in cancer therapeutics | Q35177553 | ||
| Combinations of anticancer drugs and immunotherapy | Q35207136 | ||
| Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. | Q35234948 | ||
| Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? | Q35594089 | ||
| Immunotherapy of malignant diseases. Challenges and strategies. | Q35621079 | ||
| Anticancer therapeutic potential of soy isoflavone, genistein. | Q35975993 | ||
| Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity | Q36078972 | ||
| Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin | Q36081335 | ||
| Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts | Q36108564 | ||
| Active specific immunotherapy in colon cancer | Q36112295 | ||
| Continuing challenges in childhood non-Hodgkin's lymphoma | Q36228057 | ||
| Induced sensitization of tumor stroma leads to eradication of established cancer by T cells | Q36228950 | ||
| Perspectives of immunotherapy in metastatic breast cancer. | Q36333747 | ||
| Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. | Q36372880 | ||
| Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death | Q36403093 | ||
| Therapeutic lymphoma vaccines: importance of T-cell immunity | Q36530231 | ||
| Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations | Q44664828 | ||
| Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients | Q45066205 | ||
| Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide | Q45182740 | ||
| Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy | Q45862115 | ||
| Drug-mediated immunogenic changes of virus-induced leukemia in vivo | Q45881963 | ||
| Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs | Q46227342 | ||
| Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | Q46246951 | ||
| Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities | Q46641344 | ||
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment | Q46641346 | ||
| 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. | Q46735710 | ||
| Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination | Q46859959 | ||
| Chemoimmunotherapeutic approach to prolonged survival time in combination with immunization and glutamic Acid derivatives with antitumor activity in tumor-bearing mice. | Q46867617 | ||
| Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts | Q47854934 | ||
| Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model | Q48287471 | ||
| Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. | Q50718079 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. | Q53251676 | ||
| Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. | Q53470311 | ||
| A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. | Q53561395 | ||
| Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. | Q54520670 | ||
| Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. | Q54591297 | ||
| Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. | Q55467906 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A | Q57424743 | ||
| Antigenic changes related to drug action | Q58855462 | ||
| In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo | Q58855473 | ||
| Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine | Q61788033 | ||
| Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities | Q63197865 | ||
| Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer | Q64378051 | ||
| Antigenic Changes of L5178Y Lymphoma After Treatment With 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide In Vivo 2 | Q67440168 | ||
| Correlations between humoral immunity and successful chemotherapy-immunotherapy | Q67493233 | ||
| Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma | Q68322594 | ||
| Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM) | Q68895286 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells | Q69820065 | ||
| Evaluation of lymphocyte immunity in breast cancer patients | Q70483069 | ||
| Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts | Q70487549 | ||
| Modification of tumor regression by immunologic means | Q71338053 | ||
| Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide | Q71733345 | ||
| Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 | Q72052802 | ||
| Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies | Q72856071 | ||
| Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin | Q73048337 | ||
| Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models | Q73078396 | ||
| A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas | Q73119226 | ||
| CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma | Q73181016 | ||
| CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment | Q73235541 | ||
| Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil) | Q73424522 | ||
| Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer | Q73516937 | ||
| Clearance of apoptotic and necrotic cells and its immunological consequences | Q36585103 | ||
| Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. | Q36590513 | ||
| Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer | Q36614598 | ||
| Current status of immunotherapy in B cell malignancies | Q36638492 | ||
| Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia | Q36689156 | ||
| Links between innate and cognate tumor immunity | Q36736618 | ||
| Future strategies for targeted therapies and tailored patient management in pancreatic cancer | Q36901260 | ||
| Immunotherapy for prostate cancer - recent progress in clinical trials. | Q36902793 | ||
| Ecto-calreticulin in immunogenic chemotherapy | Q36990570 | ||
| Immunological aspects of cancer chemotherapy | Q37039588 | ||
| Cancer treatment: the combination of vaccination with other therapies | Q37089001 | ||
| Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity | Q37120261 | ||
| Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes | Q37570109 | ||
| Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent | Q39629473 | ||
| Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity | Q39907004 | ||
| Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs | Q39982106 | ||
| Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. | Q40006148 | ||
| A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model | Q40099109 | ||
| Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia | Q40101776 | ||
| Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus | Q40123387 | ||
| Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. | Q40265244 | ||
| Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma | Q40333268 | ||
| In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. | Q40345495 | ||
| Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. | Q40461812 | ||
| Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. | Q40481100 | ||
| Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways | Q40575783 | ||
| Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer | Q40632020 | ||
| Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy | Q40634072 | ||
| Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate | Q40638371 | ||
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | Q40959114 | ||
| Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs | Q41069939 | ||
| B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells | Q41105180 | ||
| Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs | Q41105815 | ||
| Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. | Q41584252 | ||
| Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound | Q41610482 | ||
| A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines | Q41668009 | ||
| Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity | Q41689760 | ||
| Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses | Q42638914 | ||
| Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. | Q42829424 | ||
| Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment | Q43773475 | ||
| Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. | Q43806539 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy | Q43918508 | ||
| High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma | Q43966195 | ||
| Low doses of chemotherapy to inhibit suppressor T cells. | Q44116665 | ||
| Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells | Q44432115 | ||
| A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 | Q44435109 | ||
| Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors | Q44542342 | ||
| P433 | issue | 4 | |
| P921 | main subject | antibody | Q79460 |
| immunotherapy | Q1427096 | ||
| lymphocyte | Q715347 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 475-492 | |
| P577 | publication date | 2008-10-17 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer | |
| P478 | volume | 58 |
| Q37416204 | Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model |
| Q43165459 | Application of nanoparticles on diagnosis and therapy in gliomas. |
| Q53870991 | Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. |
| Q37892600 | Colorectal cancer vaccines in clinical trials. |
| Q48283444 | Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls |
| Q41115927 | Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression |
| Q38202569 | Epidemiology of infections in cancer patients |
| Q35564075 | Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2 |
| Q39409268 | Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect |
| Q39144327 | Immune-Mediated Therapies for Liver Cancer. |
| Q37891875 | Immunotherapy of prostate cancer: should we be targeting stem cells and EMT? |
| Q39616709 | Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. |
| Q35837949 | Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways |
| Q33823499 | Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice |
| Q36579336 | Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis |
| Q39566639 | The gene expression profile of unstimulated dendritic cells can be used as a predictor of function. |
| Q39646317 | The use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune response |
| Q37765590 | Unravelling the complexity of cancer-immune system interplay |
| Q33781142 | What's the place of immunotherapy in malignant mesothelioma treatments? |
Search more.